---
title: "Centessa Pharma Reports Positive Phase 1 Data For ORX750 In Sleep-Deprived Volunteers; Stock Up"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/213947871.md"
description: "Centessa Pharmaceuticals plc (CNTA) reported positive interim results from a Phase 1 trial of its orexin receptor 2 agonist, ORX750, in sleep-deprived volunteers. The drug demonstrated significant improvements in sleep latency and a favorable safety profile. CNTA plans to advance ORX750 into Phase 2 studies for narcolepsy and hypersomnia in Q4 2024. Following the announcement, CNTA's stock rose by 13.13% in pre-market trading."
datetime: "2024-09-10T11:58:46.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/213947871.md)
  - [en](https://longbridge.com/en/news/213947871.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/213947871.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/213947871.md) | [English](https://longbridge.com/en/news/213947871.md)


# Centessa Pharma Reports Positive Phase 1 Data For ORX750 In Sleep-Deprived Volunteers; Stock Up

Centessa Pharmaceuticals plc (CNTA) announced positive interim data from an ongoing Phase 1 trial of its highly potent and selective orexin receptor 2 (OX2R) agonist, ORX750, in acutely sleep-deprived healthy volunteers.

According to the company, ORX750 showed clinically meaningful and statistically significant improvements in mean sleep latency at the first two doses evaluated (1.0 mg and 2.5 mg) in the Maintenance of Wakefulness Test (MWT) compared to placebo.

The company noted that the 2.5 mg dose was shown to restore normative wakefulness with a mean sleep latency of 32 minutes as measured by the MWT.

ORX750 was also shown to have a favorable safety and tolerability profile with no observations of frequently reported on-target adverse events (AEs) associated with other OX2R agonists, and no cases of hepatotoxicity or visual disturbances across all three dose levels tested (1.0 mg, 2.0 mg, and 2.5 mg), as of the data cutoff date.

The company plans to rapidly advance ORX750 into Phase 2 studies in patients with narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), and idiopathic hypersomnia (IH) beginning in the fourth quarter of 2024.

In Tuesday's pre-market trading, CNTA was trading at $16.89 up $1.96 or 13.13%.

For More Cryptocurrency News, visit rttnews.com.

For comments and feedback contact: editorial@rttnews.com

Business News

### 相關股票

- [Centessa Pharmaceuticals (CNTA.US)](https://longbridge.com/zh-HK/quote/CNTA.US.md)

## 相關資訊與研究

- [Centessa Pharmaceuticals Executives Sell Shares](https://longbridge.com/zh-HK/news/279098050.md)
- [Centessa Pharmaceuticals CEO Touts ORX750 as Best-in-Class as Registration Studies Nearing Start](https://longbridge.com/zh-HK/news/279124196.md)
- [Centessa Pharmaceuticals Teases ORX750 Phase II Update, Registrational Study Start at Conference](https://longbridge.com/zh-HK/news/278277803.md)
- [Centessa Pharmaceuticals Chief Legal Officer Iqbal J. Hussain Reports Disposal of Common Shares](https://longbridge.com/zh-HK/news/274729471.md)
- [Insider Selling: Centessa Pharmaceuticals (NASDAQ:CNTA) Insider Sells 1,010 Shares of Stock](https://longbridge.com/zh-HK/news/274732988.md)